| Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients M Pirmohamed, S James, S Meakin, C Green, AK Scott, TJ Walley, ... Bmj 329 (7456), 15-19, 2004 | 4645 | 2004 |
| Drug repurposing: progress, challenges and recommendations S Pushpakom, F Iorio, PA Eyers, KJ Escott, S Hopper, A Wells, A Doig, ... Nature reviews Drug discovery 18 (1), 41-58, 2019 | 3868 | 2019 |
| Estimation of the warfarin dose with clinical and pharmacogenetic data International Warfarin Pharmacogenetics Consortium New England Journal of Medicine 360 (8), 753-764, 2009 | 1863 | 2009 |
| Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance RA Sharma, SA Euden, SL Platton, DN Cooke, A Shafayat, HR Hewitt, ... Clinical cancer research 10 (20), 6847-6854, 2004 | 1605 | 2004 |
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ... Nature genetics 41 (7), 816-819, 2009 | 1195 | 2009 |
| Pharmacodynamic and Pharmacokinetic Study of Oral Curcuma Extract in Patients with Colorectal Cancer RA Sharma, HR McLelland, KA Hill, CR Ireson, SA Euden, MM Manson, ... Clinical Cancer Research 7 (7), 1894-1900, 2001 | 1128 | 2001 |
| HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans M McCormack, A Alfirevic, S Bourgeois, JJ Farrell, D Kasperavičiūtė, ... New England Journal of Medicine 364 (12), 1134-1143, 2011 | 1111 | 2011 |
| Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes EC Davies, CF Green, S Taylor, PR Williamson, DR Mottram, ... PLoS one 4 (2), e4439, 2009 | 1004 | 2009 |
| A randomized trial of genotype-guided dosing of warfarin M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ... New England Journal of Medicine 369 (24), 2294-2303, 2013 | 973 | 2013 |
| Adverse drug reactions M Pirmohamed, AM Breckenridge, NR Kitteringham, BK Park Bmj 316 (7140), 1295-1298, 1998 | 857* | 1998 |
| Emergence and global spread of epidemic healthcare-associated Clostridium difficile M He, F Miyajima, P Roberts, L Ellison, DJ Pickard, MJ Martin, TR Connor, ... Nature genetics 45 (1), 109-113, 2013 | 839 | 2013 |
| Which drugs cause preventable admissions to hospital? A systematic review RL Howard, AJ Avery, S Slavenburg, S Royal, G Pipe, P Lucassen, ... British journal of clinical pharmacology 63 (2), 136-147, 2007 | 819 | 2007 |
| Active transport of imatinib into and out of cells: implications for drug resistance J Thomas, L Wang, RE Clark, M Pirmohamed Blood 104 (12), 3739-3745, 2004 | 800 | 2004 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ... Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011 | 775 | 2011 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ... Clinical Pharmacology & Therapeutics 102 (3), 397-404, 2017 | 645 | 2017 |
| The role of metabolic activation in drug-induced hepatotoxicity BK Park, NR Kitteringham, JL Maggs, M Pirmohamed, DP Williams Annu. Rev. Pharmacol. Toxicol. 45 (1), 177-202, 2005 | 600 | 2005 |
| Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology T Eschenhagen, T Force, MS Ewer, GW De Keulenaer, TM Suter, ... European journal of heart failure 13 (1), 1-10, 2011 | 515 | 2011 |
| Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ... Gastroenterology 141 (1), 338-347, 2011 | 510 | 2011 |
| Pharmacogenetics of warfarin: current status and future challenges M Wadelius, M Pirmohamed The pharmacogenomics journal 7 (2), 99-111, 2007 | 447 | 2007 |
| Genetic susceptibility to adverse drug reactions M Pirmohamed, BK Park Trends in pharmacological sciences 22 (6), 298-305, 2001 | 421 | 2001 |
Paula R WilliamsonDirección de correo verificada de liv.ac.uk
